Discovery and development of novel anti-cancer agents by targeting oncogenic transcription factors.

• Unité de recherche: INNOSUISSE
• Numéro de projet: 43016.1 IP-LS
• Titre du projet anglais: Discovery and development of novel anti-cancer agents by targeting oncogenic transcription factors.

Mots-clé (Anglais)

Life sciences, Pharmaceuticals

Résumé des résultats (Abstract) (Anglais)

Cellestia Biotech is a clinical stage company based in Basel, Switzerland. The company is developing first-in-class innovative anti-cancer therapies by targeting undruggable transcription factors (TFs). The aim of the study is to expand pipeline by designing and developing novel anti-cancer agents.